Aktienanalyse zu Dermata Therapeutics Inc (DRMA)DRMADermata Therapeutics Inc

Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Dermata Therapeutics Inc is not a good buy right now due to significant financial losses and declining stock performance. The current price is $1.02, with a year-to-date change of -53.21% and a one-year change of -75.83%. The company reported a net loss of $2.97 million for Q2 2026, and the RSI is at a very low 18.827, indicating oversold conditions but also a lack of buying momentum. The main risk is the ongoing financial losses, with a projected EPS of -0.74 for the last quarter, which reflects continued operational challenges.